Participant in phase III study developed unexplained illness

Company signs deals with two specialist pharmaceutical manufacturers

Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development

Data demonstrated a 90% successful lumbar vertebrae fusion rate at 24 months

Updated Date: Tue, 06 Oct 2020 00:00:00 EDT

Updated Date: Tue, 06 Oct 2020 00:00:00 EDT

Updated Date: Tue, 06 Oct 2020 00:00:00 EDT

Updated Date: Tue, 06 Oct 2020 00:00:00 EDT

Updated Date: Tue, 06 Oct 2020 00:00:00 EDT

Ear wax resistant to home treatment is a common problem. Treatment has been provided by many, if not […]